Glenmark, Cosmo get MHRA nod to market acne treatment medication in UK

Q: How long will it take to read this news story?

The story "Glenmark, Cosmo get MHRA nod to market acne treatment medication in UK" has 259 words across 8 sentences, which will take approximately 2 - 3 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Glenmark, Cosmo get MHRA nod to market acne treatment medication in UK" was covered 1 days ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 308 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #26020876</li><li>URL: https://chronographically.beamstart.com/news/glenmark-cosmo-get-mhra-nod-17391784787512</li></ul>

Business Standard Logo Business Standard 1d ago

Glenmark, Cosmo get MHRA nod to market acne treatment medication in UK - Business Standard

Quick Summary:

"Our partnership with Cosmo Pharmaceuticals plays an important role in enabling us to expand our dermatology portfolio, and we are proud to offer this new treatment to market that can improve the quality of life for those living with acne," Glenmark Pharmaceuticals President & Business Head - Europe and Emerging Markets Christoph Stoller said.

Glenmark Pharmaceuticals and Ireland-based Cosmo Pharmaceuticals NV have received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market a product for the treatment of acne vulgaris in the United Kingdom.

As part of the agreement inked in September 2023, Glenmark in-licensed the product from Cosmo Pharmaceuticals for distribution in Europe and South Africa.